科倫藥業(002422.SZ):舒更葡糖鈉注射液獲批上市
格隆匯5月8日丨科倫藥業(002422.SZ)公佈,公司子公司湖南科倫製藥有限公司的化學藥品“舒更葡糖鈉注射液”於近日獲得國家藥品監督管理局的藥品註冊批准。
舒更葡糖鈉注射液為默沙東開發的選擇性神經肌肉阻滯拮抗劑,2008年歐盟首獲批,後相繼在美國、日本等多個國家獲批上市,2017年國內批准進口,用於拮抗羅庫溴銨或維庫溴銨誘導的神經肌肉阻滯。
舒更葡糖鈉為麻醉領域近20年的重大發現,為全球首個和唯一的特異性結合性神經肌肉阻滯拮抗劑,在全麻手術中可實現迅速、高效、徹底逆轉不同深度的肌松作用,促進患者恢復自主呼吸和肢體活動能力,幫助改善患者術後康復,目前已被中國《肌肉鬆馳藥合理應用的專家共識(2017)》、法國《肌松藥和麻醉逆轉指南(2020)》等國內外權威指南或共識推薦使用。舒更葡糖鈉注射液2021年全球銷售額超過15億美元。
隨着公司舒更葡糖鈉注射液的獲批,科倫將幫助更多的全麻手術患者進入無肌松殘餘新時代,確保手術更安全。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.